TSCAN THERAPEUTICS, INC. Share-based Payment Arrangement, Expense
TSCAN THERAPEUTICS, INC. (TCRX) reported Share-based Payment Arrangement, Expense of $11.71 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-03-04
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2021-12-31 was $784.00K, a 422.67% increase year-over-year.
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2021-09-30 was $885.00K, a 591.41% increase year-over-year.
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2021-06-30 was $503.00K, a 299.21% increase year-over-year.
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2020-12-31 was $150.00K.
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2025 was $11.71M, a 22.59% increase from fiscal 2024.
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2024 was $9.55M, a 83.35% increase from fiscal 2023.
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2023 was $5.21M, a 14.44% increase from fiscal 2022.
- TSCAN THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2022 was $4.55M, a 80.88% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $11.71M 10-K · filed 2026-03-04 | |||
| 2024-12-31 | $9.55M 10-K · filed 2026-03-04 | |||
| 2023-12-31 | $5.21M 10-K · filed 2025-03-05 | |||
| 2022-12-31 | $4.55M 10-K · filed 2024-03-06 | |||
| 2021-12-31 | $784.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $1.67M derived: sum of 2 quarters · filed 2023-03-08 | $2.17M derived: sum of 3 quarters · filed 2023-03-08 | $2.52M 10-K · filed 2023-03-08 |
| 2021-09-30 | $885.00K 10-Q · filed 2021-11-10 | $1.39M derived: sum of 2 quarters · filed 2021-11-10 | $1.73M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $503.00K 10-Q · filed 2021-08-19 | $847.00K 10-Q · filed 2021-08-19 | ||
| 2020-12-31 | $150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $278.00K derived: sum of 2 quarters · filed 2022-03-09 | $404.00K derived: sum of 3 quarters · filed 2022-03-09 | $515.00K 10-K · filed 2022-03-09 |
| 2020-09-30 | $128.00K 10-Q · filed 2021-11-10 | $254.00K derived: sum of 2 quarters · filed 2021-11-10 | $365.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $126.00K 10-Q · filed 2021-08-19 | $237.00K 10-Q · filed 2021-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |